一项随机前瞻性试验，比较5-氟尿嘧啶（NSC-19893）与5-氟尿嘧啶和甲环亚硝脲（NSC-95441）治疗晚期胃肠道癌的疗效。
Randomized prospective trial comparing 5-fluorouracil (NSC-19893) to 5-fluorouracil and methyl-CCNU (NSC-95441) in advanced gastrointestinal cancer.
作者信息
Baker L H, Vaitkevicius V K, Gehan E
出版信息
Cancer Treat Rep. 1976 Jun;60(6):733-7.
PMID:954013
Abstract
The Southwest Oncology Group has confirmed the superiority of 5-fluorouracil (5-FU) and methyl-CCNU versus 5-FU weekly as treatment for patients with advanced gastrointestinal cancers. The drug combination produced a PR rate of 29.3% compared to the single-drug arm rate of 10.6%; however, the two-drug arm produced much more toxicity. Despite the improved response rate no improvement in survival was observed.
摘要
西南肿瘤协作组已证实，对于晚期胃肠道癌患者，5-氟尿嘧啶（5-FU）与甲基环己亚硝脲联合使用优于每周使用5-FU。联合用药组的缓解率为29.3%，而单药组为10.6%；然而，联合用药组产生的毒性要大得多。尽管缓解率有所提高，但未观察到生存率的改善。
Zotero 插件